Rat and cynomolgus monkey (neither pharmacologically relevant; no CD33 cross-reactivity)
“In view of the absence of cross-reactivity of gemtuzumab ozogamicin with CD33 from laboratory species, studies of kinetics in animals can only be of limited value, as there will be no binding, specific intracellular uptake, and metabolism of the conjugate that underlies its therapeutic action in humans.”
No surrogate; clinical ADC tested in non-binding rat and monkey (plus old vs new cell line bridging)
“Repeat-dose studies included six cycle intravenous toxicity studies in rats and monkeys and a six cycle comparative study in monkeys for the old and new antibody cell lines.”
✓ VerifiedFDA pharmacology/toxicology review, p. 7Source ↗